Advances in ocular implants: From geometry design to controlled drug release mechanisms
Source abstract
Abstract
The unique physiological barriers within the eye greatly impede the effective delivery of traditional drug therapies to specific intraocular target sites, leading to low bioavailability and a short duration of action. Intraocular implants placed at targeted locations via minimally invasive surgery can directly bypass these barriers. Moreover, these implants employ their morphological features to facilitate long-term, stable, and controlled drug release at the disease site. This review systematically covers the preparation processes and drug release characteristics of sheet-shaped, irregular-shaped, and cylindrical implants. Lamellar implants with a large surface area offer rapid drug release, thereby enhancing therapeutic efficiency; irregular implants provide more precise and personalized therapeutic solutions by adapting to the anatomical structure of the eye; and cylindrical implants demonstrate stable and slow release with a uniform diffusion pathway, which can maintain the drug concentration for several months. The in-depth discussion of the release mechanism regarding the implant-based drug delivery is also included. Nevertheless, contemporary research on ocular implants continues to encounter challenges, including limited drug-loading capacity and inadequate accuracy in predicting in vivo release kinetics. In the future, a combination of computational simulation, smart-responsive materials, and nanotechnology with the current strategies for implant preparation will be necessary to optimize implant design and accelerate their translation to clinical applications. STATEMENT OF SIGNIFICANCE: The field of ocular drug delivery faces persistent challenges in overcoming physiological barriers. Ocular implants, when placed at targeted sites via minimally invasive surgery, can bypass these barriers directly. Their tailored geometries and controlled release mechanisms further enable long-acting therapeutic strategies. The current review systematically elaborates on drug release kinetics and tissue integration capacity of ocular implants with different geometric characteristics, e.g., sheet-shaped, cylindrical, and irregular implants. By stating current advances and addressing existing research gaps, this review aims to establish a theoretical framework for the rational design of ocular implants, ultimately facilitating the improvement of clinical outcomes in the management of ocular diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Ocular Disorders and Treatments · Advanced Drug Delivery Systems · Intraocular Surgery and Lenses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Recent advances of ocular drug delivery systems: prominence of ocular implants for chronic eye diseases10.3390/pharmaceutics15061746 ↗
2. Ocular drug delivery: a comprehensive review10.1208/s12249-023-02516-9 ↗
3. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis10.1016/S2214-109X(17)30293-0 ↗
4. Target strategies for drug delivery bypassing ocular barriers
5. Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration10.1016/j.jconrel.2023.09.021 ↗
6. Intractable ocular diseases and treatment progress10.1208/s12249-020-01774-1 ↗
7. Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics10.1007/s10792-023-02637-x ↗
8. Ocular biomaterials and implants10.1016/S0142-9612(00)00237-4 ↗
9. Efficacy of intravitreal dexamethasone implant (Ozurdex®) in naïve and refractory patients with different morphological subtypes of diabetic macular edema
10. Fluocinolone acetonide implant for uveitis: dissecting responder and non-responder outcomes at a tertiary center10.3390/biomedicines12051106 ↗
11. Long-acting fluocinolone acetonide intravitreal implant for recurrent bilateral non-infectious posterior uveitis
12. Indicators of post-operative intraocular pressure elevation after naive fluocinolone acetonide surgical implantation10.1080/09273948.2019.1624778 ↗
13. Ranibizumab injection (Susvimo) implant septum dislodgement in a patient with neovascular age-related macular degeneration10.1001/jamaophthalmol.2022.2495 ↗
14. Tablet geometry effect on the drug release profile from a hydrogel-based drug delivery system10.3390/pharmaceutics15071917 ↗
15. Theoretical study of diffusional release of a dispersed solute from cylindrical polymeric matrix: a novel configuration for providing zero-order release profile10.1016/j.apm.2019.03.044 ↗
16. Theoretical investigation of drug release from planar matrix systems: effects of a finite dissolution rate10.1016/S0168-3659(03)00338-9 ↗
17. Global prevalence of cataract surgery10.1097/ICU.0000000000001092 ↗
18. Diet, exercise, and lifestyle in glaucoma: current evidence and future perspectives10.3390/nu17213369 ↗
19. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy10.1016/j.gendis.2021.02.009 ↗
20. The evolution of diabetic retinopathy screening10.1038/s41433-025-03633-4 ↗
21. Pathophysiology and management of glaucoma and ocular hypertension related to trauma10.1016/j.survophthal.2020.02.003 ↗
22. 1α, 25-dihydroxyvitamin D3 protects retinal ganglion cells in glaucomatous mice10.1186/s12974-021-02263-3 ↗
23. Glaucoma: an extension of various chronic neurodegenerative disorders10.1007/s12035-013-8416-8 ↗
24. Global estimates on the number of people blind or visually impaired by glaucoma: a meta-analysis from 2000 to 202010.1038/s41433-024-02995-5 ↗
25. The aqueous humor outflow pathways in glaucoma: a unifying concept of disease mechanisms and causative treatment10.1016/j.ejpb.2015.04.029 ↗
26. Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway10.1080/14728222.2017.1386174 ↗
27. The exit strategy: pharmacological modulation of extracellular matrix production and deposition for better aqueous humor drainage10.1016/j.ejphar.2016.04.048 ↗
28. A new polymeric minimally invasive glaucoma implant
29. Biological macromolecules for ophthalmic drug delivery to treat ocular diseases10.1016/j.ijbiomac.2018.01.120 ↗
30. Cataracts10.1016/S0140-6736(17)30544-5 ↗
31. Drug delivery to the lens for the management of cataracts10.1016/j.addr.2018.03.009 ↗
32. Age-related macular degeneration: a disease of extracellular complement amplification10.1111/imr.13145 ↗
33. Age-related macular degeneration: a review10.1001/jama.2023.26074 ↗
34. The natural history and prognosis of neovascular age-related macular degeneration10.1016/j.ophtha.2007.03.008 ↗
35. Immunology of age-related macular degeneration10.1038/nri3459 ↗
36. Associations between the complement system and choroidal neovascularization in wet age-related macular degeneration10.3390/ijms21249752 ↗
37. Treatment for neovascularage related macular degeneration: the state of the art10.1016/j.ejphar.2016.03.002 ↗
38. Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update10.1007/s40259-021-00499-2 ↗
39. New therapeutic targets in the treatment of age-related macular degeneration. Nuevas dianas terapeuticas an el tratamiento de la degeneracion macular asociada a la edad10.1016/j.oftal.2019.09.011 ↗
40. No CFH or ARMS2 interaction with omega-3 fatty acids, low versus high zinc, or β-carotene versus lutein and zeaxanthin on progression of age-related macular degeneration in the age-related eye disease study 2 age-related eye disease study 2 report no. 1810.1016/j.ophtha.2019.06.004 ↗
41. One-year outcome of combination therapy with full or reduced photodynamic therapy and one anti-vascular endothelial growth factor in pachychoroid neovasculopathy10.3390/ph15040483 ↗
42. Global prevalence of diabetic retinopathy and projection of burden through 2045 systematic review and meta-analysis10.1016/j.ophtha.2021.04.027 ↗
43. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 204010.1016/j.diabres.2017.03.024 ↗
44. The danish registry of diabetic retinopathy10.2147/CLEP.S99507 ↗
45. Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies10.1155/2019/4940825 ↗
46. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy results from the panorama randomized clinical trial10.1001/jamaophthalmol.2021.2809 ↗
47. Current management of diabetic tractional retinal detachments10.4103/ijo.IJO_1217_18 ↗
48. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations
49. Drug delivery strategies to improve the treatment of corneal disorders10.1016/j.heliyon.2025.e41881 ↗
50. Drug transport by the blood-aqueous humor barrier of the eye10.1124/dmd.116.069369 ↗
51. Topical and systemic drug delivery to the posterior segments10.1016/j.addr.2005.09.004 ↗
52. Drug delivery to the posterior segment of the eye10.5301/EJO.2010.6051 ↗
53. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies10.1016/j.addr.2022.114342 ↗
54. Barrier analysis of periocular drug delivery to the posterior segment10.1016/j.jconrel.2010.08.028 ↗
55. Treatment avenues for age-related macular degeneration: breakthroughs and bottlenecks10.1016/j.arr.2024.102322 ↗
56. Protein delivery for retinal diseases: from basic considerations to clinical applications10.1016/j.preteyeres.2010.04.001 ↗
57. Tight junctions of the outer blood retina barrier10.3390/ijms21010211 ↗
58. Metabolomics studies in common multifactorial eye disorders: a review of biomarker discovery for age-related macular degeneration, glaucoma, diabetic retinopathy and myopia10.3389/fmolb.2024.1403844 ↗
59. Intravitreal drug delivery in retinal disease: are we out of our depth10.1517/17425247.2014.927864 ↗
60. Misdirected aqueous flow in rhegmatogenous retinal detachment: a pathophysiology update10.1016/j.survophthal.2014.07.002 ↗
61. Intravitreal clearance and volume of distribution of compounds in rabbits: in silico prediction and pharmacokinetic simulations for drug development10.1016/j.ejpb.2015.01.003 ↗
62. The vitreous, the retinal interface in ocular health and disease10.1159/000353447 ↗
63. Polymer-based carriers for ophthalmic drug delivery10.1016/j.jconrel.2018.06.031 ↗
64. Eco polymeric materials and natural polymer10.3390/polym15194021 ↗
65. Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin10.1167/iovs.12-10717 ↗
66. Strategies for improving ocular drug bioavailability and corneal wound healing with chitosan-based delivery systems10.3390/polym10111221 ↗
67. Chitosan as a wound dressing starting material: antimicrobial properties and mode of action10.3390/ijms20235889 ↗
68. Chitosan-based functional materials for skin wound repair: mechanisms and applications10.3389/fbioe.2021.650598 ↗
69. Chitosan lysozyme conjugates for enzyme-triggered hydrogel degradation in tissue engineering applications10.1021/acsami.8b15591 ↗
70. Modified hyaluronic acid with enhanced resistance to degradation10.1016/j.carbpol.2023.121241 ↗
71. A comprehensive review on the role of polymers in ocular drug delivery10.2174/1567201820666230110140312 ↗
72. Recent advances in gelatin-based therapeutics10.1080/14712598.2019.1610383 ↗
73. Corneal regeneration: a review of stromal replacements10.1016/j.actbio.2018.01.023 ↗
74. Gelatin-based particulate systems in ocular drug delivery10.3109/10837450.2014.999786 ↗
75. Role of solvent-mediated carbodiimide cross-linking in fabrication of electrospun gelatin nanofibrous membranes as ophthalmic biomaterials10.1016/j.msec.2016.11.105 ↗
76. Cellulose and its derivatives: structure, modification, and application in controlled drug delivery10.1186/s43094-025-00834-2 ↗
77. Hydroxypropyl methylcellulose: physicochemical properties and ocular drug delivery formulations10.1016/j.ejps.2021.105736 ↗
78. Considerations for polymers used in ocular drug delivery10.3389/fmed.2021.787644 ↗
79. Efficacy of polyethylene glycol–propylene glycol-based lubricant eye drops in reducing squamous metaplasia in patients with dry eye disease10.2147/OPTH.S164888 ↗
80. Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye10.1136/bjophthalmol-2016-308608 ↗
81. Clinical evaluation of the efficacy of peg/pg lubricant eye drops with gelling agent (hp-guar) for the relief of the signs and symptoms of dry eye disease: a review10.1358/dot.2007.43.12.1162080 ↗
82. Comparison of the efficacy of carboxymethylcellulose 0.5%, hydroxypropyl-guar containing polyethylene glycol 400/propylene glycol, and hydroxypropyl methyl cellulose 0.3% tear substitutes in improving ocular surface disease index in cases of dry eye10.4103/meajo.MEAJO_165_15 ↗
83. Pegylation for enhancing nanoparticle diffusion in mucus10.1016/j.addr.2017.08.010 ↗
84. Poly-ε-caprolactone intravitreous devices: an in vivo study10.1167/iovs.08-2969 ↗
85. Synthesis, microstructure and mechanical properties of partially biobased biodegradable poly(ethylene brassylate-co-ε-caprolactone) copolyesters10.1016/j.jmbbm.2018.12.019 ↗
86. Development of besifloxacin HCL loaded nanofibrous ocular inserts for the treatment of bacterial keratitis: in vitro, ex vivo and in vivo evaluation10.1016/j.ijpharm.2020.119552 ↗
87. A biodegradable ocular implant for long-term suppression of intraocular pressure10.1007/s13346-015-0240-4 ↗
88. Polylactic acid (PLA) controlled delivery carriers for biomedical applications10.1016/j.addr.2016.06.018 ↗
89. Intravitreal poly(l-lactide) microparticles sustain retinal and choroidal delivery of tg-0054, a hydrophilic drug intended for neovascular diseases10.1007/s13346-010-0009-8 ↗
90. Biodegradable PLGA-based drug delivery systems for modulating ocular surface disease under experimental murine dry eye10.4172/2155-9570.1000191 ↗
91. Effect of modifications in poly (lactide-co-glycolide) (PLGA) on drug release and degradation characteristics: a mini review10.2174/1567201818666210510165938 ↗
92. Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles
93. A novel method for preparing surface-modified fluocinolone acetonide loaded plga nanoparticles for ocular use: in vitro and in vivo evaluations10.1208/s12249-015-0448-0 ↗
94. Polymeric materials for eye surface and intraocular applications10.1021/acs.biomac.0c01525 ↗
95. Highly transparent covalent mucin coatings improve the wettability and tribology of hydrophobic contact lenses10.1021/acsami.0c06847 ↗
96. Impact of a hyaluronic acid-grafted layer on the surface properties of model silicone hydrogel contact lenses10.1021/acs.langmuir.8b01693 ↗
97. Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an ex vivo corneal model10.1016/j.ijpharm.2019.05.031 ↗
98. Surface morphological modification of crosslinked hydrophilic co-polymers by nanosecond pulsed laser irradiation10.1016/j.apsusc.2016.02.047 ↗
99. Synthesis and evaluation of mucoadhesive acryloyl-quaternized PDMAEMA nanogels for ocular drug delivery10.1016/j.colsurfb.2017.04.050 ↗
100. Ophthalmic drug delivery